- Home
- VTLE vs ERAS Comparison
VTLE vs ERAS Comparison
Compare VTLE & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTLE
- ERAS
- Stock Information
- Founded
- VTLE 2006
- ERAS 2018
- Country
- VTLE United States
- ERAS United States
- Employees
- VTLE N/A
- ERAS N/A
- Industry
- VTLE
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- VTLE
- ERAS Health Care
- Exchange
- VTLE Nasdaq
- ERAS Nasdaq
- Market Cap
- VTLE 560.8M
- ERAS 484.4M
- IPO Year
- VTLE 2011
- ERAS 2021
- Fundamental
- Price
- VTLE $15.33
- ERAS $1.64
- Analyst Decision
- VTLE Hold
- ERAS Strong Buy
- Analyst Count
- VTLE 11
- ERAS 6
- Target Price
- VTLE $26.63
- ERAS $4.83
- AVG Volume (30 Days)
- VTLE 1.3M
- ERAS 796.3K
- Earning Date
- VTLE 08-06-2025
- ERAS 08-12-2025
- Dividend Yield
- VTLE N/A
- ERAS N/A
- EPS Growth
- VTLE N/A
- ERAS N/A
- EPS
- VTLE N/A
- ERAS N/A
- Revenue
- VTLE $1,935,411,000.00
- ERAS N/A
- Revenue This Year
- VTLE $3.06
- ERAS N/A
- Revenue Next Year
- VTLE N/A
- ERAS N/A
- P/E Ratio
- VTLE N/A
- ERAS N/A
- Revenue Growth
- VTLE 5.26
- ERAS N/A
- 52 Week Low
- VTLE $12.30
- ERAS $1.01
- 52 Week High
- VTLE $38.02
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- VTLE 40.32
- ERAS 58.30
- Support Level
- VTLE $14.13
- ERAS $1.38
- Resistance Level
- VTLE $15.78
- ERAS $1.71
- Average True Range (ATR)
- VTLE 1.00
- ERAS 0.11
- MACD
- VTLE -0.22
- ERAS 0.01
- Stochastic Oscillator
- VTLE 18.88
- ERAS 78.95
About VTLE Vital Energy Inc. par value $0.01 per share
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.